Hanson Pharmaceuticals announced that HS-20093, a B7-H3 targeting antibody-drug conjugate independently developed by the company, reached the main end of overall survival in critical phase III clinical trials for patients with small cell lung cancer that progressed or recurred after platinum-containing treatment. When analyzed during the pre-set period, compared with topotecan, HS-20093 showed statistically significant and clinically significant improvements in OS. Consistent benefits were also observed during survival without progression at secondary endpoints, and safety characteristics were consistent with previous study results. The company will begin communication with regulators in the near future to advance preparations for new drug marketing applications in China.

Hanson Pharmaceuticals announced that HS-20093, a B7-H3 targeting antibody-drug conjugate independently developed by the company, reached the main end of overall survival in critical phase III clinical trials for patients with small cell lung cancer that progressed or recurred after platinum-containing treatment. When analyzed during the pre-set period, compared with topotecan, HS-20093 showed statistically significant and clinically significant improvements in OS. Consistent benefits were also observed during survival without progression at secondary endpoints, and safety characteristics were consistent with previous study results. The company will begin communication with regulators in the near future to advance preparations for new drug marketing applications in China.